Aptose Biosciences Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 22

  • Investments
  • 1

Aptose Biosciences General Information

Description

Aptose Biosciences Inc is a clinical-stage biotechnology company. Its compound tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild-type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases, while avoiding many typical toxicity concerns observed with other agents. The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed patients with AML who are ineligible to receive induction chemotherapy. The group has reported data from the first three dose cohorts that demonstrated safety, CRs, and minimal residual disease (MRD) negativity across patients with diverse mutations.

Contact Information

Website
www.aptose.com
Formerly Known As
Lorus Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 66 Wellington Street West
  • Suite 5300, TD Bank Tower, Box 48
  • Toronto, Ontario M5K 1E6
  • Canada
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 66 Wellington Street West
  • Suite 5300, TD Bank Tower, Box 48
  • Toronto, Ontario M5K 1E6
  • Canada
+1 (858)

Aptose Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aptose Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aptose Biosciences‘s full profile, request access.

Request a free trial

Aptose Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Aptose Biosciences Inc is a clinical-stage biotechnology company. Its compound tuspetinib is a convenient once daily ora
Drug Discovery
Toronto, Canada
14 As of 2025

Austin, TX
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aptose Biosciences Competitors (56)

One of Aptose Biosciences’s 56 competitors is Rein Therapeutics, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rein Therapeutics Formerly VC-backed Austin, TX
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Kite Pharma Formerly VC-backed Santa Monica, CA
XBiotech Corporation Austin, TX
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 56 competitors. Get the full list »

Aptose Biosciences Patents

Aptose Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4630122-A1 Methods for treating patients with hematologic malignancies Pending 10-Dec-2022
US-20260199335-A1 Methods for treating patients with hematologic malignancies Pending 10-Dec-2022
WO-2024124199-A1 Methods for treating patients with hematologic malignancies Inactive 10-Dec-2022
WO-2024124199-A9 Methods for treating patients with hematologic malignancies Inactive 10-Dec-2022
WO-2021247717-A1 2-indolyl imidazo [4,5-d] phenanthroline polymorphs and compositions regarding the same Inactive 02-Jun-2020 C07D471/14
To view Aptose Biosciences’s complete patent history, request access »

Aptose Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aptose Biosciences Investments (1)

Aptose Biosciences’s most recent deal was a Corporate Asset Purchase with CrystalGenomics (China rights to CG-806) for . The deal was made on 14-Jun-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CrystalGenomics (China rights to CG-806) 14-Jun-2018 Corporate Asset Purchase Buildings and Property
To view Aptose Biosciences’s complete investments history, request access »

Aptose Biosciences FAQs

  • When was Aptose Biosciences founded?

    Aptose Biosciences was founded in 1986.

  • Where is Aptose Biosciences headquartered?

    Aptose Biosciences is headquartered in Toronto, Canada.

  • What is the size of Aptose Biosciences?

    Aptose Biosciences has 14 total employees.

  • What industry is Aptose Biosciences in?

    Aptose Biosciences’s primary industry is Drug Discovery.

  • Is Aptose Biosciences a private or public company?

    Aptose Biosciences is a Private company.

  • What is the current valuation of Aptose Biosciences?

    The current valuation of Aptose Biosciences is .

  • What is Aptose Biosciences’s current revenue?

    The current revenue for Aptose Biosciences is .

  • How much funding has Aptose Biosciences raised over time?

    Aptose Biosciences has raised $236M.

  • Who are Aptose Biosciences’s competitors?

    Rein Therapeutics, Inovio Pharmaceuticals, Kite Pharma, XBiotech, and Oncorus are some of the 56 competitors of Aptose Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process